CRISPR Therapeutics (NASDAQ:CRSP) is one of the stocks that should double by 2030. On January 30, Citizens maintained an ...

CRISPR Therapeutics heads into Q4 earnings with rising Casgevy sales, collaboration revenues from Vertex, and a history of beating estimates.

Nobel laureate Jennifer Doudna, PhD; Matthew Porteus, MD, PhD, and Rodolphe Barrangou, PhD—offer their views on the commercial potential and challenges of genome editing following a rollercoaster 2025 ...

Artificial intelligence (AI) isn't the only industry with explosive growth potential.

We sifted through several financial media reports and stock screeners to compile a list of the top stocks that will double in ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...

CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports ...

NTLA stock faces binary risk: success could unlock multi-billion dollar markets, while setbacks may erase hundreds of ...

Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ: CRSP), has come under renewed pressure in recent weeks, ...

Why CRISPR Therapeutics Is On Investors’ Radar Today CRISPR Therapeutics (CRSP) has attracted fresh attention after recent trading left the stock around $54.65, with performance mixed over the past ...

The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial.

ARK Invest bought $10.4M in Joby Aviation stock after a 16.7% drop and sold Teradyne near highs on January 29, 2026. Full trade breakdown here.